DrugPatentWatch Database Preview
Drugs in Development Information for GDC-0349
Email this page to a colleague
What is the drug development status for GDC-0349?
GDC-0349 is an investigational drug.
There have been 178 clinical trials for GDC-0349.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Summary for GDC-0349
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 111 |
| WIPO Patent Applications | 102 |
| Japanese Patent Applications | 37 |
| Clinical Trial Progress | Phase 3 (2010-07-01) |
| Vendors | 34 |
Recent Clinical Trials for GDC-0349
| Title | Sponsor | Phase |
|---|---|---|
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Kazia Therapeutics Limited | Phase 2 |
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Lakshmi Nayak | Phase 2 |
| A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy | Shanghai Jiao Tong University School of Medicine | Phase 2 |
Clinical Trial Summary for GDC-0349
Top disease conditions for GDC-0349
Top clinical trial sponsors for GDC-0349
US Patents for GDC-0349
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
